Description
Starpharma Holdings (ASX: SPL) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. The lead pharmaceutical development product is VivaGel®, a vaginal microbicide designed to prevent the transmission of HIV and genital herpes.
Starpharma is developing a VivaGel®-coated condom under a licence agreement with SSL International plc (LSE:SSL), manufacturer of Durex®, the market-leading condom brand worldwide. Products based on Starpharma’s technology are on the market as diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA. Starpharma is exploring dendrimer opportunities in materials science applications including water remediation and animal health products.
Share Price
In-depth Starpharma Holdings Proactive Investors Articles
- 12/11/2009 Starpharma Holdings updates shareholders at AGM, share price out-performs ASX 200 Index
- 05/11/2009 New agreement deals Starpharma Holdings into US$35.8b pesticides market
- 04/08/2009 Starpharma trims net loss and reports encouraging results from VivaGel® clinical trial
- 27/07/2009 Starpharma Holdings reduces operating costs, builds momentum in revenues from partnering technology
Recent Starpharma Holdings news
- 12/03/2010 Starpharma Holdings reports positve results from VivaGel® clinical trial
- 11/02/2010 Starpharma Holdings cashed up, strong 2010 pipeline
- 01/02/2010 Starpharma Holdings and Eli Lilly ink new drug delivery collaboration in human pharmaceuticals
- 29/01/2010 Starpharma Holdings maintains healthy $24.3m in cash reserves
- 18/11/2009 Starpharma Holdings raises $15.6m, placement oversubscribed
Presentations & Company Media
Related Research & Media
Current Operations:
.gif)
Dendrimers
Traditionally, "well defined" complex macromolecules such as proteins were largely found only in natural systems. However, using Starpharma's dendrimer technology, it is possible to create precisely-defined synthetic complex macromolecules that are applicable to a wide range of medical uses.
One important property of dendrimers is “polyvalency” or the presence of multiple active groups on the surface of the dendrimer. This is significant because simultaneous presentation of active groups can yield entirely new or enhanced activity compared to single presentation of the same active group.
Starpharma's current development programs are in the areas of:
* HIV
* Genital herpes
* Other VivaGel® indications such as HPV, bacterial vaginosis
and Contraception
* Drug delivery
* siRNA delivery
* Other life science and industrial applications for dendrimers
The properties of Starpharma’s dendrimers make them suitable for pharmaceutical applications. For example, they are well defined chemical entities, which simplifies the regulatory process for their approval. They are also "biofriendly", being made predominantly from the amino acid, lysine.(Read More)
Management
Peter T Bartels AO - Chairman and Non-executive Director
John Raff, Dip Ag Sc, BSc, PhD - Deputy Chairman and Non-executive Director
Jackie Fairley, BSc, BVSc (Hons), MBA - Chief Executive Officer
Ross Dobinson, BBus (Acc) - Non-executive Director
Richard A Hazleton - Non-executive Director
BSChE, MSChE, HonDrEngr, HonDrCommSci
Peter J Jenkins, MB, BS (Melb), FRACP - Non-executive Director
For more information click here
Major Shareholders
Contact Information
Starpharma Holdings Ltd
Postal Address:
PO Box 6535
St Kilda Road Central VIC 8008
AUSTRALIA
Street Address:
Baker Building
75 Commercial Road
Melbourne VIC 3004
AUSTRALIA
T: +61 3 8532 2700
F: +61 3 9510 5955
Corporate Information
No info available.
Investors interested in Starpharma Holdings recently viewed:
- Access Pharmaceuticals (OTCBB: .ACCP)
- Alliance Pharma plc (AIM: APH)
- Amphion Innovations (LON: AMP)
- Asterand (LSE: ATD)
- Biocompatibles (LSE: BII)
- BioNeutral Group (OTCBB: .BONU)
- Bionomics Limited (ASX: .BNO)
- Circadian Technologies Limited (ASX: .CIR)
- CogState Limited (ASX: .CGS)
- Eco Animal Health Group Plc (AIM: EAH)
- Epistem (AIM: EHP)
- ImmuPharma Plc (AIM: IMM)
- Lipoxen Plc (AIM: LPX)
- Medical Australia Limited (ASX: MLA)
- Oxford Nutrascience (AIM: ONG)
- QRxPharma Ltd (ASX: QRX)
- Renovo Group Plc (LSE: RNVO)
- Rexahn Pharmaceuticals (AMEX: RNN)
- Stirling Products Limited (ASX: .STI)